Next Pharmaceuticals Acquires Sytrinol
SALINAS, CA, Jun 05, 2013 Next Pharmaceuticals has purchased worldwide distribution rights, along with all patents, trademarks and scientific knowledge for Sytrinol from KGK Synergize. Sytrinol is currently sold through Proprietary Nutritionals Inc., who holds distribution rights through December 31, 2013.
PNI to Distribute Sytrinol 12/09/2008
LONDON, Ontario—KGK Synergize selected Kearny, N.J.-based Proprietary Nutritionals Inc. (PNI) as the exclusive worldwide distributor of its proprietary ingredient Sytrinol®, effective Jan. 1, 2009. Sytrinol, a patented combination of polymethoxylated flavones and tocotrienols, has been shown in clinical trials to lower cholesterol by up to 30 percent. PNI’s parent company, Pharmachem Laboratories, will assume manufacturing of Sytrinol to further ensure the ingredient’s quality and consistency.